dermatologyadvisor13h
Positive Results for Tremfya in Low Body Surface Area Psoriasis
Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...
FierceBiotech15h
Innovent, awaiting Chinese regulators' verdict, posts another psoriasis win for IL-23 drug
The anti-IL-23 monoclonal antibody, called picankibart, was shown to clear or nearly clear all lesions after 16 weeks among 48.2% of the 82 participating Chinese patients that were classified as ...
BioSpace18h
Lilly and J&J Face Off in Crohn’s Disease With Phase III Readouts at ACG 2024
Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s ...